Research programme: nanoemulsion-based influenza virus vaccines - NanoBio

Drug Profile

Research programme: nanoemulsion-based influenza virus vaccines - NanoBio

Alternative Names: NanoVax®-Panflu; NE-rH5 vaccine

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator NanoBio Corporation
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 27 Jul 2016 Preclinical development is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (IM, Injection)
  • 29 Oct 2013 NanoBio Corporation receives contract from National Institute of Allergy and Infectious Diseases for nanoemulsion-based influenza virus vaccine development in pandemic Influenza virus infections (prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top